The Blue Venture Fund
VC Fund
Chicago, United States
The Blue Venture Fund is a strategic investment vehicle that aims to foster innovation within the healthcare system. The Blue Venture Fund invests in emerging healthcare companies that have the potential to improve the quality of care, enhance patient experience, and reduce costs. It seeks to support companies that align with the needs and priorities of Blue Cross Blue Shield (BCBS) member companies and their policyholders.
- Total investments:
- 127
- Last investment:
- Lead investor:
- 35%
- Fund size:
- $10M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries The Blue Venture Fund invests in
Stages The Blue Venture Fund invests in
Countries The Blue Venture Fund invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $2.4M–$25M
- Series B
- $5.5M–$36M
- Series C
- $12M–$64M
Investment Focus
Industry
- Health Care 52 (41%)
- Medical 21 (17%)
- Wellness 16 (13%)
- Software 14 (11%)
- Information Technology 12 (9%)
Stage
- Series A 28 (22%)
- Series B 22 (17%)
- Series C 15 (12%)
- Seed 12 (9%)
- Venture - Series Unknown 8 (6%)
Country
- United States 65 (51%)
- United Kingdom 2 (2%)
- India 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
John Banta
President and Managing Director
|
President and Managing Director | Total investments: 5 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Network Bio is a clinical and molecular data library enabling precision medicine approaches for common human diseases. Its platform delivers a centralized repository for clinical and molecular data that allows researchers to identify patterns and correlations that can be used to develop new treatments and diagnostic tools. | $50M / Venture - Series Unknown / Aug 19, 2026 | ||
| Big Health is a digital therapeutics company that operates a digital healthcare portal to offer fully-automated and highly personalized digital therapeutics and behavioral programs for mental health issues. Its portal offers an online personalized medicine-care and prepares a sleep improvement program in consultation with medical professionals thatenable individuals to overcome their sleep-related disorders in an efficient manner. | $23.7M / Venture - Series Unknown / Feb 12, 2026 | ||
| Origin provides physical therapy services. They focus on pregnancy, postpartum, menopause, and sexual health. They also offer physical therapy for the pelvic floor and the whole body. | Series B / Jan 28, 2026 | ||
| Nest Health offers medical services that aim to minimize the stress of arranging childcare, making travel arrangements, and leaving home. The company offers a wide range of services to newborns, babies, children, teens, and adults for medical, behavioral, nutrition, and more, enabling patients to get treated at home. | $10M / Series A / Nov 21, 2025 | ||
| Daymark Health is a cancer care company that focuses on providing in-home and virtual supportive care to cancer patients in collaboration with health plans. The company offers a wide range of supportive care services, including behavioral health care and social support, aimed at meeting the comprehensive needs of cancer patients. Daymark Healthconnects primary care physicians, oncologists, and other care teams to create a seamless and supportive experience for patients, leveraging both virtual and home-based care methodologies. | $20M / Series A / Sep 25, 2025 | ||
| Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States. | $35.6M / Series C / Sep 04, 2025 | ||
| Noctrix Health is an early-stage medical device company that focuses on developing a revolutionary therapy for a chronic illness. | $33.5M / Venture - Series Unknown / Aug 29, 2025 | ||
| Nest Health offers medical services that aim to minimize the stress of arranging childcare, making travel arrangements, and leaving home. The company offers a wide range of services to newborns, babies, children, teens, and adults for medical, behavioral, nutrition, and more, enabling patients to get treated at home. | $12.5M / Series A / Aug 25, 2025 | ||
| Ultromics develops AI-powered software solutions to assist in cardiovascular disease diagnosis through echocardiography. The company provides platforms that support clinicians in interpreting echocardiogram data by applying machine learning to detect patterns and abnormalities that may indicate heart conditions. Ultromics offers its flagshipproduct, EchoGo, which automates the analysis of echocardiograms and delivers quantitative reports on cardiac function and structure. The software integrates with existing clinical workflows and is designed to enhance decision-making consistency while reducing variability in scan interpretation. Ultromics focuses on leveraging data-driven approaches to support early detection of conditions such as heart failure and coronary artery disease. Its technology is built on research collaborations and large-scale clinical datasets, aiming to improve diagnostic outcomes and support clinical efficiency. | $55M / Series C / Jul 31, 2025 | ||
| PinkDx is a biotechnology company. | $5M / Series A / Jan 23, 2025 | ||
| See all 127 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does The Blue Venture Fund invest in?
The Blue Venture Fund invests primarily in Health Care, Medical and Wellness startups, most often at Series A and Series B stage. Most of the 127 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does The Blue Venture Fund invest in?
The Blue Venture Fund typically joins rounds of $2.4M–$25M at Series A, $5.5M–$36M at Series B and $12M–$64M at Series C. These are whole funding-round sizes, not The Blue Venture Fund's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds The Blue Venture Fund took part in.
How do I contact The Blue Venture Fund?
Public channels for The Blue Venture Fund include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at The Blue Venture Fund?
The team at The Blue Venture Fund includes John Banta (President and Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
